SCN5A and Brugada syndrome: Finally, we examined the effectiveness of the nonselective sodium current inhibitor flecainide, an antiarrhythmic useful in the control of a variety of supraventricular cardiac tachyarrhythmias, including those bearing SCN5A mutations underlying Brugada syndrome (Salvage et al. 2017).